130 related articles for article (PubMed ID: 38051169)
1. Biennial Endoscopic Surveillance of Gastrointestinal Metaplasia and Its Subtypes Reduces Gastric Cancer Mortality and Is Cost-Effective in a Markov State Transition Model.
Becker EC; Salunke R; Saraceni C; Birk J
South Med J; 2023 Dec; 116(12):951-956. PubMed ID: 38051169
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Impact and Cost-Effectiveness of Surveillance of Incidentally Detected Gastric Intestinal Metaplasia: A Microsimulation Analysis.
Thiruvengadam NR; Gupta S; Buller S; Awad I; Gandhi D; Ibarra A; Latorre G; Riquelme A; Kochman ML; Cote G; Shah SC; Saumoy M
Clin Gastroenterol Hepatol; 2024 Jan; 22(1):51-61. PubMed ID: 37302442
[TBL] [Abstract][Full Text] [Related]
3. Endoscopy for Gastric Cancer Screening Is Cost Effective for Asian Americans in the United States.
Shah SC; Canakis A; Peek RM; Saumoy M
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):3026-3039. PubMed ID: 32707341
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Gastric Cancer Screening According to Race and Ethnicity.
Saumoy M; Schneider Y; Shen N; Kahaleh M; Sharaiha RZ; Shah SC
Gastroenterology; 2018 Sep; 155(3):648-660. PubMed ID: 29778607
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy.
Huang RJ; Ende AR; Singla A; Higa JT; Choi AY; Lee AB; Whang SG; Gravelle K; D'Andrea S; Bang SJ; Schmidt RA; Yeh MM; Hwang JH
Gastrointest Endosc; 2020 Jan; 91(1):70-77.e1. PubMed ID: 31425693
[TBL] [Abstract][Full Text] [Related]
6. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
Kowada A
Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
[TBL] [Abstract][Full Text] [Related]
7. High-risk symptoms do not predict gastric cancer precursors.
Da B; Jani N; Gupta N; Jayaram P; Kankotia R; Yao Yu C; Dinis-Ribeiro M; Buxbaum J
Helicobacter; 2019 Feb; 24(1):e12548. PubMed ID: 30412322
[TBL] [Abstract][Full Text] [Related]
8. How Do We Manage Gastric Intestinal Metaplasia? A Survey of Clinical Practice Trends for Gastrointestinal Endoscopists in the United States.
Vance RB; Kubiliun N; Dunbar KB
Dig Dis Sci; 2016 Jul; 61(7):1870-8. PubMed ID: 26984230
[TBL] [Abstract][Full Text] [Related]
9. Adequacy of endoscopic recognition and surveillance of gastric intestinal metaplasia and atrophic gastritis: A multicentre retrospective study in low incidence countries.
Honing J; Keith Tan W; Dieninyte E; O'Donovan M; Brosens L; Weusten B; di Pietro M
PLoS One; 2023; 18(6):e0287587. PubMed ID: 37352223
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer.
Yeh JM; Hur C; Kuntz KM; Ezzati M; Goldie SJ
Cancer; 2010 Jun; 116(12):2941-53. PubMed ID: 20564399
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Gastric Intestinal Metaplasia: Current Status and Future Directions.
Huang RJ; Choi AY; Truong CD; Yeh MM; Hwang JH
Gut Liver; 2019 Nov; 13(6):596-603. PubMed ID: 31394893
[TBL] [Abstract][Full Text] [Related]
12. A Population-Based Helicobacter pylori Eradication Strategy Is More Cost-Effective than Endoscopic Screening.
Kowada A
Dig Dis Sci; 2023 May; 68(5):1735-1746. PubMed ID: 36565366
[TBL] [Abstract][Full Text] [Related]
13. Risk of Gastric Cancer Among Patients With Intestinal Metaplasia of the Stomach in a US Integrated Health Care System.
Reddy KM; Chang JI; Shi JM; Wu BU
Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1420-5. PubMed ID: 27317852
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival.
Yeh JM; Ho W; Hur C
Gastrointest Endosc; 2010 Jul; 72(1):33-43. PubMed ID: 20430384
[TBL] [Abstract][Full Text] [Related]
15. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of
Kowada A
Scand J Gastroenterol; 2019 Jun; 54(6):685-689. PubMed ID: 31190581
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia.
Hassan C; Zullo A; Di Giulio E; Annibale B; Lahner E; De Francesco V; Ierardi E
Helicobacter; 2010 Jun; 15(3):221-6. PubMed ID: 20557364
[TBL] [Abstract][Full Text] [Related]
18. Subtyping intestinal metaplasia in patients with chronic atrophic gastritis: an interobserver variability study.
Lerch JM; Pai RK; Brown I; Gill AJ; Jain D; Kővári B; Kushima R; Sheahan K; Slavik T; Srivastava A; Lauwers GY; Langner C
Pathology; 2022 Apr; 54(3):262-268. PubMed ID: 35221041
[TBL] [Abstract][Full Text] [Related]
19. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies.
Areia M; Carvalho R; Cadime AT; Rocha Gonçalves F; Dinis-Ribeiro M
Helicobacter; 2013 Oct; 18(5):325-37. PubMed ID: 23566268
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer.
Laszkowska M; Truong H; Faye AS; Kim J; Tan SX; Lim F; Abrams JA; Hur C
Dig Dis Sci; 2022 Aug; 67(8):3693-3701. PubMed ID: 34657192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]